Charles Schwab Investment Management Inc. Buys 39,850 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Charles Schwab Investment Management Inc. raised its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 7.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 565,503 shares of the company's stock after buying an additional 39,850 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.96% of Protagonist Therapeutics worth $25,448,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. grew its holdings in shares of Protagonist Therapeutics by 405,061.2% in the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company's stock valued at $78,034,000 after purchasing an additional 1,733,662 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth $861,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Protagonist Therapeutics in the 3rd quarter worth about $5,665,000. Moran Wealth Management LLC increased its holdings in shares of Protagonist Therapeutics by 27.6% in the 3rd quarter. Moran Wealth Management LLC now owns 15,030 shares of the company's stock worth $676,000 after buying an additional 3,250 shares during the last quarter. Finally, Segall Bryant & Hamill LLC raised its position in shares of Protagonist Therapeutics by 1.5% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 120,301 shares of the company's stock valued at $5,414,000 after buying an additional 1,739 shares in the last quarter. Institutional investors own 98.63% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on PTGX shares. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Wedbush restated an "outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. The Goldman Sachs Group started coverage on Protagonist Therapeutics in a research report on Friday. They issued a "neutral" rating and a $47.00 price target for the company. Truist Financial began coverage on shares of Protagonist Therapeutics in a research report on Monday, September 9th. They set a "buy" rating and a $60.00 price objective on the stock. Finally, StockNews.com upgraded shares of Protagonist Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $53.78.

Protagonist Therapeutics Stock Up 2.2 %

PTGX stock traded up $0.90 during trading on Friday, hitting $42.58. The company had a trading volume of 204,569 shares, compared to its average volume of 745,452. Protagonist Therapeutics, Inc. has a 52-week low of $19.00 and a 52-week high of $48.89. The company has a 50 day simple moving average of $44.81 and a 200-day simple moving average of $40.06. The firm has a market capitalization of $2.54 billion, a P/E ratio of 15.67 and a beta of 2.18.

Insider Transactions at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 1,906 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the transaction, the insider now owns 46,444 shares of the company's stock, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of Protagonist Therapeutics stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $46.96, for a total value of $3,687,299.20. Following the completion of the sale, the chief executive officer now owns 435,208 shares of the company's stock, valued at $20,437,367.68. The trade was a 15.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 232,066 shares of company stock valued at $10,681,738. 5.40% of the stock is currently owned by company insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.